Peer-reviewed veterinary case report
Iron levels and anemia treatment with darbepoetin alfa in dogs
By Bhamarasuta, Chayanont et al.·Published in The Journal of veterinary medical science·2021·Department of Physiology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease.
- Species:
- dog
Plain-English summary
A group of dogs with chronic kidney disease (CKD) were studied to see how their iron levels affected their response to a treatment called darbepoetin alfa, which helps with anemia (low red blood cell count). The researchers found that dogs who responded well to the treatment had higher iron levels before starting it, while those who didn't respond had lower iron levels. After 28 days of treatment, the dogs that responded showed an increase in their red blood cell count, indicating the treatment was effective for them. This suggests that monitoring iron levels could help predict how well CKD dogs will respond to anemia treatments.
People also search for: dog chronic kidney disease anemia treatment · darbepoetin alfa for dogs · dog iron levels and kidney disease
Abstract
Iron metabolism, hepcidin and some blood profiles were investigated in 13 healthy and 31 chronic kidney disease (CKD) dogs. The study consisted of 2 experiments, experiment I included healthy dogs (CONT) and CKD dogs (stage 2, 3 and 4), while experiment II consisted of anemic CKD dogs subjected to 28-day darbepoetin alfa treatment. The response to darbepoetin alfa could divide anemic CKD dogs into responder (RP) and non-responder (NRP) subgroups. The results from experiment I showed that packed cell volume (PCV) and plasma albumin concentration were significantly lower in CKD dogs of all stages while the total iron binding capacity (TIBC) was lower in only CKD stage 3 and 4 compared with dogs in CONT group. The PCV was related to both TIBC and albumin when considering among all dogs or only in CKD dogs. The hepcidin concentration in CKD dogs with anemia was lower than those without anemia (P<0.05). In experiment II before darbepoetin alfa treatment, RP subgroup had significantly higher iron and TIBC compared with NRP subgroup (P<0.05), the iron concentration was decreased only in RP subgroup after darbepoetin alfa treatment (P<0.05). The percent increase in PCV was correlated with initial TIBC (P<0.01). Plasma hepcidin concentration was not different between CONT and CKD groups and between RP and NRP subgroups both before and after darbepoetin alfa treatment. It is concluded that TIBC and plasma iron concentration play role on anemia and erythropoietic response to darbepoetin alfa treatment in CKD dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33563860/